Allergopharma Joachim Ganzer KG, Hermann-Koerner-Strasse 52, 21465 Reinbek, Germany.
Curr Top Microbiol Immunol. 2011;352:27-42. doi: 10.1007/82_2011_129.
Numerous allergens have been cloned and produced by the use of recombinant DNA technology. In several cases recombinant variants with reduced IgE-reactivity have also been developed as candidates for allergen specific immunotherapy. Only very few of these proteins have as yet been tested in the clinic, and the major focus has been on birch and grass pollen, two of the most common causes of IgE-mediated allergic disease. This article serves to justify the rational for using recombinant products and reviews the progress that has been made to date with their clinical assessment.
许多过敏原已经通过重组 DNA 技术被克隆和生产。在几种情况下，还开发了具有降低 IgE 反应性的重组变体作为变应原特异性免疫治疗的候选物。这些蛋白质中只有极少数已经在临床上进行了测试，主要集中在桦树和草花粉上，这两种是最常见的 IgE 介导的过敏性疾病的原因。本文旨在证明使用重组产品的合理性，并回顾迄今为止在其临床评估方面取得的进展。
